Shire to undertake more study of ProAmatine
This article was originally published in Scrip
Shire said on 2 December that it plans to conduct two trials of ProAmatine (midodrine) to meet requirements for the accelerated approval the drug's new drug application (NDA) was granted in 1996 by the US FDA as a treatment for patients with symptomatic orthostatic hypotension (SOH), a condition that affects about 60,000 people in the US causing a sudden decrease in blood pressure attributed to cardiovascular, endocrine or neurological disorders.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.